Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Cassava Sciences (NASDAQ:FLNA – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.
Risk and Volatility
Madrigal Pharmaceuticals has a beta of -1.07, meaning that its stock price is 207% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.71, meaning that its stock price is 171% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and target prices for Madrigal Pharmaceuticals and Cassava Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 1 | 3 | 13 | 1 | 2.78 |
| Cassava Sciences | 1 | 0 | 1 | 0 | 2.00 |
Institutional and Insider Ownership
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Madrigal Pharmaceuticals and Cassava Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | -27.32% | -50.15% | -25.44% |
| Cassava Sciences | N/A | -53.90% | -34.20% |
Valuation and Earnings
This table compares Madrigal Pharmaceuticals and Cassava Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $1.13 billion | 9.60 | -$288.28 million | ($12.80) | -36.82 |
| Cassava Sciences | N/A | N/A | -$90.97 million | ($1.61) | -0.82 |
Cassava Sciences has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Madrigal Pharmaceuticals beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About Cassava Sciences
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
